Halozyme Therapeutics Inc.
Organization details
- Legal name
- Halozyme Therapeutics Inc.
- Former names
- Global Yacht Services Inc
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- SAN Diego
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- HALO
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001159036
- EIN
- 88-0488686
- Wikidata ID
- Q5643474
Board of directors
-
Akiko Moni Miyashita · DirectorSince 2023
-
Barbara Gayle Duncan · DirectorSince 2023
-
Bernadette Connaughton · DirectorSince 2023
-
Connie Matsui · DirectorSince 2023
-
Dannielle Appelhans · DirectorSince 2026
-
Helen Torley · Director · PRESIDENT AND CEOSince 2023
-
James M. Daly · DirectorSince 2026
-
James Paul Lang · DirectorSince 2025
-
Jean-Pierre Bizzari · DirectorSince 2023
-
Jeffrey William Henderson · DirectorSince 2023
-
Mahesh Krishnan · DirectorSince 2024
-
Matthew L. Posard · DirectorSince 2023
Chief executives
Director election results
Annual meeting of May 1, 2025. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
96.8%
-
99.2%
Board connections
9 of this board's directors also sit on 17 other boards. 13 are in the same sector.
-
ACADIA Pharmaceuticals Inc. Same sectorvia James M. Daly
-
ADC Therapeutics SA Same sectorvia Jean-Pierre Bizzari
-
Aprea Therapeutics Inc. Same sectorvia Jean-Pierre Bizzari
-
Artelo Biosciences Inc. Same sectorvia Connie Matsui
-
Atea Pharmaceuticals Inc. Same sectorvia Barbara Gayle Duncan
- via Akiko Moni Miyashita
-
Becton Dickinson and Company Same sectorvia Jeffrey William Henderson
-
BioVie Inc. Same sectorvia James Paul Lang
-
Cytokinetics Incorporated Same sectorvia James M. Daly
-
Editas Medicine Inc. Same sectorvia Bernadette Connaughton
-
Kyntra Bio Inc. Same sectorvia Jeffrey William Henderson
-
Madrigal Pharmaceuticals Inc. Same sectorvia James M. Daly
- via Matthew L. Posard
- via James Paul Lang
-
Ovid Therapeutics Inc. Same sectorvia Barbara Gayle Duncan
- via Jeffrey William Henderson
-
Sutro Biopharma Inc. Same sectorvia Connie Matsui
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $45,209,288
- 99 sales by 5 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 8, 2026 | Helen Torley Director, Officer (PRESIDENT AND CEO) | Option exercise | +20,000 | $18.41 | $368,200 |
| Oct 8, 2026 | Helen Torley Director, Officer (PRESIDENT AND CEO) | Open-market sale | −4,810 | $108.18 | $520,341 |
| Oct 8, 2026 | Helen Torley Director, Officer (PRESIDENT AND CEO) | Open-market sale | −3,090 | $108.91 | $336,526 |
| Oct 8, 2026 | Helen Torley Director, Officer (PRESIDENT AND CEO) | Open-market sale | −11,900 | $110.00 | $1,308,941 |
| Oct 8, 2026 | Helen Torley Director, Officer (PRESIDENT AND CEO) | Open-market sale | −200 | $110.51 | $22,102 |
| Oct 7, 2026 | Helen Torley Director, Officer (PRESIDENT AND CEO) | Option exercise | +20,000 | $18.41 | $368,200 |
| Oct 7, 2026 | Helen Torley Director, Officer (PRESIDENT AND CEO) | Open-market sale | −8,600 | $111.03 | $954,867 |
| Oct 7, 2026 | Helen Torley Director, Officer (PRESIDENT AND CEO) | Open-market sale | −10,300 | $111.84 | $1,151,942 |
| Oct 7, 2026 | Helen Torley Director, Officer (PRESIDENT AND CEO) | Open-market sale | −900 | $112.78 | $101,502 |
| Oct 7, 2026 | Helen Torley Director, Officer (PRESIDENT AND CEO) | Open-market sale | −200 | $113.69 | $22,739 |
| Oct 6, 2026 | Helen Torley Director, Officer (PRESIDENT AND CEO) | Option exercise | +20,000 | $18.41 | $368,200 |
| Oct 6, 2026 | Helen Torley Director, Officer (PRESIDENT AND CEO) | Open-market sale | −2,300 | $107.90 | $248,175 |
| Oct 6, 2026 | Helen Torley Director, Officer (PRESIDENT AND CEO) | Open-market sale | −6,000 | $109.33 | $656,004 |
| Oct 6, 2026 | Helen Torley Director, Officer (PRESIDENT AND CEO) | Open-market sale | −9,920 | $109.89 | $1,090,119 |
| Oct 6, 2026 | Helen Torley Director, Officer (PRESIDENT AND CEO) | Open-market sale | −1,780 | $110.81 | $197,245 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Halozyme Therapeutics Inc.
Who is the CEO of Halozyme Therapeutics Inc.?
Helen Torley is Halozyme Therapeutics Inc.'s PRESIDENT AND CEO.
How many directors are on Halozyme Therapeutics Inc.'s board?
Halozyme Therapeutics Inc.'s board has 12 directors: Akiko Moni Miyashita, Barbara Gayle Duncan, Bernadette Connaughton, Connie Matsui, Dannielle Appelhans, Helen Torley, James M. Daly, James Paul Lang, Jean-Pierre Bizzari, Jeffrey William Henderson and 2 others.
Are Halozyme Therapeutics Inc. insiders buying or selling shares?
Over the last 12 months, Halozyme Therapeutics Inc. insiders made no open-market purchases and sold $45.2 million of shares in 99 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="halozyme-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.